Kodiak Sciences (KOD) Expected to Announce Earnings on Wednesday

Key Points

• Kodiak Sciences is expected to report Q1 2026 results before the market opens on May 13, with analysts projecting EPS of ($0.93); an earnings call is scheduled for May 14 at 4:00 PM ET.
• The company missed estimates last quarter with EPS of ($1.04), and analysts project approximately ($4) EPS for both the current and next fiscal years.
• Shares trade around $42.66 (52‑week range $2.81–$47.84) with a $2.65B market cap, while recent analyst action includes price-target increases (UBS $80, HC Wainwright $58) and an average target of $35.43 with a "Moderate Buy" consensus.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) is projected to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.93) per share for the quarter. Investors can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($1.04) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). On average, analysts expect Kodiak Sciences to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kodiak Sciences Trading Up 0.9%

Shares of KOD stock opened at $42.66 on Wednesday. The company's fifty day simple moving average is $34.26 and its 200-day simple moving average is $27.18. Kodiak Sciences has a 52 week low of $2.81 and a 52 week high of $47.84. The company has a market cap of $2.65 billion, a PE ratio of -9.88 and a beta of 2.32.

Analysts Set New Price Targets

A number of equities analysts have recently commented on KOD shares. Weiss Ratings reissued a "sell (e+)" rating on shares of Kodiak Sciences in a research note on Thursday, January 22nd. HC Wainwright reissued a "buy" rating and issued a $58.00 target price (up from $38.00) on shares of Kodiak Sciences in a research note on Friday, March 27th. Finally, UBS Group raised their target price on shares of Kodiak Sciences from $50.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, March 27th. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $35.43.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in KOD. Headlands Technologies LLC grew its holdings in Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock worth $30,000 after acquiring an additional 5,815 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Kodiak Sciences during the 1st quarter worth $94,000. BNP Paribas Financial Markets grew its holdings in Kodiak Sciences by 89.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company's stock worth $104,000 after acquiring an additional 3,009 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Kodiak Sciences during the 4th quarter worth $119,000. Finally, Jane Street Group LLC grew its holdings in Kodiak Sciences by 441.3% during the 1st quarter. Jane Street Group LLC now owns 64,649 shares of the company's stock worth $181,000 after acquiring an additional 52,705 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.